Cell death and cancer therapy

Current Opinion in Pharmacology

Volumn 1, Issue 4, 2001, Pages 337-341

  Bunz, Fred ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Anticancer; Apoptosis; Cancer Biology; Chemoresistance; Molecular Medicine; Pathway; Pharmacology; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

ANIMAL; APOPTOSIS; CELL DEATH; DRUG EFFECT; GENETICS; HUMAN; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; GENES, BCL-2; GENES, P53; HUMANS; NEOPLASMS;

EID: 0035434444     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(01)00059-5     Document Type: Review

References (46)

1. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature. 408:2000;433-439.
2. Lowe S.W., Lin A.W. Apoptosis in cancer. Carcinogenesis. 21:2000;485-495.
3. Ionov Y., Yamamoto H., Krajewski S., Reed J.C., Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci USA. 97:2000;10872-10877. Inactivating frameshift mutations in Bax can be selected for during xenograft tumor development, demonstrating that loss of apoptosis can confer a selective growth advantage in vivo.
4. Brown J.M., Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1999;1391-1399.
5. Tannock I.F., Lee C. Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs. Br J Cancer. 84:2001;100-105.
6. Schmitt C.A., Rosenthal C.T., Lowe S.W. Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med. 6:2000;1029-1035. This report highlights the problems with the systems currently used to evaluate cellular response to therapy and demonstrates the importance of studying tumors in situ.
7. Reed J.C. Dysregulation of apoptosis in cancer. J Clin Oncol. 17:1999;2941-2953.
8. Green D.R. Apoptotic pathways: paper wraps stone blunts scissors. Cell. 102:2000;1-4.
9. Zou H., Li Y., Liu X., Wang X. An APAF-1:cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem. 274:1999;11549-11556.
10. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1999;1899-1911.
11. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
12. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:1998;491-501.
13. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
14. Vousden K.H. p53. Death star. Cell. 103:2000;691-694.
15. Soengas M.S., Alarcon R.M., Yoshida H., Giaccia A.J., Hakem R., Mak T.W., Lowe S.W. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 284:1999;156-159. A genetic demonstration that p53 is upstream in the pathway of mitochondria-dependent apoptosis.
16. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M., Friedman S.L., Galle P.R., Stremmel W., Oren M., et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 188:1998;2033-2045.
17. Wu G.S., Kim K., El-Deiry W.S. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv Exp Med Biol. 465:2000;143-151.
18. Lin Y., Ma W., Benchimol S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet. 26:2000;122-127.
19. Meng R.D., McDonald E.R., Sheikh M.S., Fornace A.J., El-Deiry W.S. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther. 1:2000;130-144.
20. Ding H.F., Lin Y.L., McGill G., Juo P., Zhu H., Blenis J., Yuan J., Fisher D.E. Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. J Biol Chem. 275:2000;38905-38911.
21. Chao C., Saito S., Kang J., Anderson C.W., Appella E., Xu Y. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J. 19:2000;4967-4975.
22. Jimenez G.S., Nister M., Stommel J.M., Beeche M., Barcarse E.A., Zhang X.Q., O'Gorman S., Wahl G.M. A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat Genet. 26:2000;37-43.
23. Kemp C.J., Sun S., Gurley K.E. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Res. 61:2001;327-332. Tumors in different tissues of the mouse are differentially sensitive to DNA-damaging agents in their ability to activate p53-dependent apoptosis. Such experiments demonstrate that different pathways are active in different cell types and offer clues as to why certain kinds of mutations predominate in different cancers.
24. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., Housman D.E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
25. Bunz F., Hwang P.M., Torrance C., Waldman T., Zhang Y., Dillehay L., Williams J., Lengauer C., Kinzler K.W., Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 104:1999;263-269. In a single cell population, p53 can cause apoptosis in response to one drug and cell-cycle arrest in response to another.
26. Yin C., Knudson C.M., Korsmeyer S.J., Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 385:1997;637-640.
27. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T., Tokino T., Taniguchi T., Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 288:2000;1053-1058. NOXA creates a potentially useful link between p53 and the gene family that regulates mitochondrial stability and apoptosis. Drugs that induce NOXA may provide a way, in some cell types, of circumventing the drug resistance associated with p53 mutation.
28. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell. 102:2000;849-862.
29. Yu J., Zhang L., Hwang P.M., Kinzler K.W., Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell. 7:2001;673-682.
30. Nakano K., Vousden K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 7:2001;683-694.
31. Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
32. Kagawa S., Gu J., Swisher S.G., Ji L., Roth J.A., Lai D., Stephens L.C., Fang B. Antitumor effect of adenovirus-mediated Bax gene transfer on p53- sensitive and p53-resistant cancer lines. Cancer Res. 60:2000;1157-1161.
33. Kim R., Minami K., Nishimoto N., Toge T. Enhancement of antitumor effect by intratumoral administration of Bax gene in combination with anticancer drugs in gastric cancer. Int J Oncol. 18:2001;363-367.
34. Zhang L., Yu J., Park B.H., Kinzler K.W., Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science. 290:2000;989-992. Loss of BAX causes a loss of the apoptotic response of colon cancer cells to nonsteroidal anti-inflamatory drugs, demonstrating a common link between cancer genetics, tumor evolution and cancer prevention.
35. Jansen B., Wacheck V., Heere-Ress E., Schlagbauer-Wadl H., Hoeller C., Lucas T., Hoermann M., Hollenstein U., Wolff K., Pehamberger H. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet. 356:2000;1728-1733. A clinical application of basic cell biology: using antisense drugs against anti-apoptotic genes to sensitize tumors to apoptosis-inducing drugs.
36. Chin L., Merlino G., DePinho R.A. Malignant melanoma: modern black plague and genetic black box. Genes Dev. 12:1998;3467-3481.
37. Castellano M., Parmiani G. Genes involved in melanoma: an overview of INK4a and other loci. Melanoma Res. 9:1999;421-432.
38. Soengas M.S., Capodieci P., Polsky D., Mora J., Esteller M., Opitz-Araya X., McCombie R., Herman J.G., Gerald W.L., Lazebnik Y.A., et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature. 409:2001;207-211. Epigenetic silencing of the APAF-1 locus can contribute to the treatment failure of malignant melanoma, raising the possibility that such an alteration could be pharmacologically reversed for therapeutic benefit.
39. Jones P.A. Cancer. Death and methylation. Nature. 409:2001;141-144.
40. Yang Y.L., Li X.M. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res. 10:2000;169-177.
41. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., Altieri D.C. Control of apoptosis and mitotic spindle checkpoint by Survivin. Nature. 396:1998;580-584.
42. Ambrosini G., Adida C., Altieri D.C. A novel anti-apoptosis gene, Survivin, expressed in cancer and lymphoma. Nat Med. 3:1997;917-921.
43. Grossman D., Kim P.J., Schechner J.S., Altieri D.C. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA. 98:2001;635-640.
44. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., MacGregor G.R., Thompson C.B., Korsmeyer S.J. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 292:2001;727-730.
45. Shi Y. A structural view of mitochondria-mediated apoptosis. Nat Struct Biol. 8:2001;394-401.
46. Fisher D.E. The p53 tumor suppressor: critical regulator of life and death in cancer. Apoptosis. 6:2001;7-15.